Design and in vitro evaluation of folate-targeted, co-drug encapsulated theranostic liposomes for non-small cell lung cancer

Karpuz, Merve; Silindir-Gunay, Mine; Kursunel, M. Alper; Esendağlı, Güneş; Doğan, Aydın; Özer, A. Yekta

doi:10.1016/j.jddst.2020.101707

Cited by 21 publications

(12 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The whole amount of CMS was released from cationic and neutral liposome at the end of 8 h and 10 h, respectively. Our findings are similar with the literature for different hydrophilic drugs [14a, 28]. The release of CMS in cationic liposome was found to be faster compared to neutral liposome due to the existence of charged lipids in the formulation [29].…”

Section: Resultssupporting

confidence: 91%

Electrochemical Analysis of Liposome‐encapsulated Colistimethate Sodium

2022

Self Cite

View full text Add to dashboard Cite

In this study, the neutral and cationic liposomal formulations of Colistimethate sodium (CMS), an antibiotic for multi‐drug resistant gram‐negative bacteria, were prepared and electrochemical quantification of CMS from these liposomes were achieved. This is the first study of the electrochemical detection of CMS released from liposomes. First, the electrochemical properties of CMS were analysed, then the encapsulation efficiency, and the release kinetic of CMS from liposomes were determined with Differential Pulse Voltammetry (DPV) measurements. In addition, Cyclic Voltammetry were applied to determine oxidation signal of CMS. A higher encapsulation efficiency was found in the cationic liposome compared to the neutral liposome. Moreover, CMS was controlled released from liposomes with zero‐order drug release kinetics.

show abstract

Section: Resultssupporting

confidence: 91%

Electrochemical Analysis of Liposome‐encapsulated Colistimethate Sodium

2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…According to our previous results (Karpuz et al, 2020(Karpuz et al, , 2023, higher encapsulation efficiency was achieved for hydrophilic drugs such as IMT using the similar rate with 8:2 (PC:Chol). Therefore, liposomes were prepared by lipid film-hydration technique by using the lipid ratios comprising 80% of phospholipid and %20 of cholesterol similar to the literature (Sun et al, 2017).…”

mentioning

confidence: 66%

⁶⁸Ga‐labeled, imatinib encapsulated, theranostic liposomes: Formulation, characterization, and in vitro evaluation of anticancer activity

Karpuz,

Ozgenc,

Oner

et al. 2023

Drug Development Research

Self Cite

View full text Add to dashboard Cite

Cancer is still a global health problem. Among cancer types, breast cancer is the most frequently diagnosed one, and it causes a high mortality rate if not diagnosed in the early stages. In our study, imatinib encapsulated, nanosized, neutral/cationic liposome formulations were prepared as theranostic agents for breast cancer. After the characterization studies in which all liposomes exhibited proper profile owing to their particle size between 133 and 250 nm, polydispersity index values lower than 0.4, neutral and cationic zeta potential values, and high drug encapsulation efficiency, controlled drug release behaviors with zero‐order kinetic were obtained. The higher than 90% radiolabeling efficiency values were obtained thanks to the determination of optimum radiolabeling condition (80°C temperature, 5 mCi radioactivity, and 10 min incubation period). According to the resazurin assay evaluating the cytotoxic profile of liposomes on MCF7 cells, neutral empty liposome was found as biocompatible, while both cationic liposomes (empty and drug‐loaded ones) exhibited high nonspecific cytotoxicity at even low drug concentration due to the existence of stearyl amine in the formulations. However, dose‐dependent cytotoxic effect and the highest cellular binding capacity were obtained by imatinib loaded neutral liposomes. In conclusion, 68Ga‐radiolabeled, imatinib‐loaded, neutral, nanosized liposome formulation is the most promising one as a theranostic agent among all formulations.

show abstract

“…Lectin-mediated drug delivery uses endogenous ligands such as lactose, fructose, fucose, mannose, and galactose (Kesharwani et al, 2011). Among them, galactose is one of the most utilized ligands targeting lectin molecules.…”

Section: Galactosementioning

confidence: 99%

Ligand conjugated lipid‐based nanocarriers for cancer theranostics

Kumar

Dkhar

Kumari

et al. 2022

Biotech & Bioengineering

View full text Add to dashboard Cite

Cancer is one of the major health‐related issues affecting the population worldwide and subsequently accounts for the second‐largest death. Genetic and epigenetic modifications in oncogenes or tumor suppressor genes affect the regulatory systems that lead to the initiation and progression of cancer. Conventional methods, including chemotherapy/radiotherapy/appropriate combinational therapy and surgery, are being widely used for theranostics of cancer patients. Surgery is useful in treating localized tumors, but it is ineffective in treating metastatic tumors, which spread to other organs and result in a high recurrence rate and death. Also, the therapeutic application of free drugs is related to substantial issues such as poor absorption, solubility, bioavailability, high degradation rate, short shelf‐life, and low therapeutic index. Therefore, these issues can be sorted out using nano lipid‐based carriers (NLBCs) as promising drug delivery carriers. Still, at most, they fail to achieve site‐targeted drug delivery and detection. This can be achieved by selecting a specific ligand/antibody for its cognate receptor molecule expressed on the surface of the cancer cells. In this review, we have mainly discussed the various types of ligands used to decorate NLBCs. A list of the ligands used to design nanocarriers to target malignant cells has been extensively undertaken. The approved ligand‐decorated lipid‐based nanomedicines with their clinical status have been explained in tabulated form to provide a wider scope to the readers regarding ligand‐coupled NLBCs.

show abstract

Design and in vitro evaluation of folate-targeted, co-drug encapsulated theranostic liposomes for non-small cell lung cancer

Cited by 21 publications

References 38 publications

Electrochemical Analysis of Liposome‐encapsulated Colistimethate Sodium

Electrochemical Analysis of Liposome‐encapsulated Colistimethate Sodium

⁶⁸Ga‐labeled, imatinib encapsulated, theranostic liposomes: Formulation, characterization, and in vitro evaluation of anticancer activity

Ligand conjugated lipid‐based nanocarriers for cancer theranostics

Contact Info

Product

Resources

About

Design and in vitro evaluation of folate-targeted, co-drug encapsulated theranostic liposomes for non-small cell lung cancer

Cited by 21 publications

References 38 publications

Electrochemical Analysis of Liposome‐encapsulated Colistimethate Sodium

Electrochemical Analysis of Liposome‐encapsulated Colistimethate Sodium

68Ga‐labeled, imatinib encapsulated, theranostic liposomes: Formulation, characterization, and in vitro evaluation of anticancer activity

Ligand conjugated lipid‐based nanocarriers for cancer theranostics

Contact Info

Product

Resources

About

⁶⁸Ga‐labeled, imatinib encapsulated, theranostic liposomes: Formulation, characterization, and in vitro evaluation of anticancer activity